Sevelamer Hydrochloride Tablet bulk supplier for pharma manufacturers

Sevelamer Hydrochloride Tablet 400 mg, 800 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 400 mg, 800 mg

Reference Brands: Renagel (USA)

Sevelamer Hydrochloride is a non-calcium, non-metal-based phosphate binder used to control serum phosphorus levels in patients with chronic kidney disease (CKD) who are on dialysis. It works by binding phosphate from dietary sources in the gastrointestinal tract, preventing its absorption into the bloodstream. This helps reduce hyperphosphatemia and supports better management of kidney-related complications.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Sevelamer is a phosphate-binding medication used to manage hyperphosphatemia in patients with chronic kidney disease, particularly those on dialysis. It works by binding to dietary phosphate in the gastrointestinal tract when taken with meals, preventing its absorption and helping to maintain balanced phosphate levels in the blood. This action reduces the risk of complications associated with high phosphate levels, such as bone and cardiovascular disorders. Sevelamer was originally invented and developed by GelTex Pharmaceuticals and is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate). Available in oral formulations, sevelamer provides a non-calcium, non-metal-based option for controlling hyperphosphatemia, offering an effective and well-tolerated approach for long-term management in chronic kidney disease patients. Its use supports better overall patient outcomes by helping to regulate phosphate levels safely without adding extra calcium or aluminum load.

Sevelamer Hydrochloride Tablet — third party manufacturing & bulk supply

Sevelamer Hydrochloride Tablet 400 mg, 800 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Sevelamer Hydrochloride Tablet is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Sevelamer Hydrochloride Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Sevelamer Hydrochloride Tablet →

Back to Listing

Frequently Asked Questions

Sevelamer hydrochloride is used to control high blood phosphate levels in patients with chronic kidney disease, particularly those on dialysis. It helps prevent complications related to hyperphosphatemia, such as bone and cardiovascular problems.

Sevelamer hydrochloride is a non-absorbed, polymeric amine compound that binds phosphate in the gastrointestinal tract, reducing its absorption into the bloodstream.

Sevelamer hydrochloride is marketed under trade names such as Renagel and Renvela (depending on region and formulation).

The original branded product Renagel was developed and marketed by Genzyme (now part of Sanofi). Multiple generic manufacturers also produce sevelamer hydrochloride worldwide.

The generic name is sevelamer hydrochloride.

Common brand names include Renagel and Renvela.

Sevelamer hydrochloride is manufactured in several countries including the USA, EU nations, and other regulated markets by approved pharmaceutical manufacturers following international quality and regulatory standards.